Antibody drug conjugates (ADCs) are a innovative class of targeted cancer therapies. Comprising monoclonal antibodies, ADCs deliver potent cytotoxic agents directly to cancer cells, minimizing damage to healthy tissue. The antibody component selectively binds to specific proteins on cancer cells, facilitating targeted drug delivery. Once bound, the conjugate releases a toxic payload, inducing cell death. ADCs showcase precision and efficacy, offering a promising approach to treat various cancers with reduced side effects, potentially revolutionizing oncology treatment strategies.
Data Bridge Market Research analyzes that the Global Antibody Drug Conjugates (ADC) Market, which was USD 4,750.00 million in 2022, is expected to reach USD 26,040.61 million by 2030, and is expected to undergo a CAGR of 23.7% during the forecast period of 2023 to 2030.
"Advancements in antibody technology drive the market growth"
Continuous progress in antibody technology is propelling the antibody drug conjugates (ADC) market forward. Innovations in antibody engineering enhance the specificity and affinity of monoclonal antibodies, crucial components of ADCs. These advancements enable more precise targeting of cancer cells, optimizing therapeutic effects. Additionally, improvements in linker technology and payload delivery systems enhance drug stability and efficacy. The evolving landscape of antibody technology contributes to the development of increasingly sophisticated ADCs, driving therapeutic advancements and expanding the potential applications of this promising class of cancer treatments.
What restraints the growth of the global antibody drug conjugates (ADC) market?
" High development costs hamper the market growth"
High development costs pose a significant hindrance to the antibody drug conjugates (ADC) market. The intricate nature of ADCs, combining monoclonal antibodies with potent drugs, demands rigorous research and testing, elevating total expenses. This financial burden restrains market growth, limiting accessibility and affordability of advanced therapies. The formidable investment required for ADC development creates challenges in realizing their full potential, impeding progress in the field of targeted cancer treatments.
Segmentation: Global Antibody Drug Conjugates (ADC) Market
The global antibody drug conjugates (ADC) market is segmented on the basis of target, product, mechanism of action, technology, indication, end-users, and distribution channel.
- On the basis of target, the global antibody drug conjugates (ADC) market is segmented into antibody-protein toxin conjugates, antibody-chelated radionuclide conjugates, antibody-small-molecule drug conjugates, and antibody-enzyme conjugates
- On the basis of product, the global antibody drug conjugates (ADC) market is segmented into ADCERTIS, KADCYLA, and others
- On the basis of mechanism of action, the global antibody drug conjugates (ADC) market is segmented into CD30 antibodies, and HER2 antibodies
- On the basis of technology, the global antibody drug conjugates (ADC) market is segmented into immunogen technology, seattle genetics technology, immunomedics technology, and others
- On the basis of indication, the global antibody drug conjugates (ADC) market is segmented into lymphoma, breast cancer, brain tumor, lung cancer, ovarian cancer, and others
- On the basis of end-users, the global antibody drug conjugates (ADC) market is segmented into hospitals, specialty clinics, and others
- On the basis of distribution channel, the global antibody drug conjugates (ADC) market is segmented into hospital pharmacy, retail pharmacy, and others
Regional Insights: North America is expected to dominate the Global Antibody Drug Conjugates (ADC) Market
North America is expected to dominate the global antibody drug conjugates (ADC) market, driven by factors such as escalating healthcare costs, a surge in research and development initiatives, and the adoption of cutting-edge technologies. This regional dominance reflects a confluence of economic strength and innovation, positioning North America as a pivotal player in shaping the trajectory of the ADC market on a global scale.
Asia-Pacific is expected to dominate the global antibody drug conjugates (ADC) market during the forecast period from 2023 to 2030. This growth is propelled by the region's accelerated pace, driven by key market players' strategic initiatives and supportive government programs. The favorable environment for ADC development positions Asia-Pacific as a frontrunner, poised for significant advancements in this crucial segment of the pharmaceutical industry.
Recent Developments: Global Antibody Drug Conjugates (ADC) Market
- In 2021, Daiichi Sankyo achieved FDA accelerated approval for Enhertu (trastuzumab deruxtecan) to treat locally advanced or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma. This marked a significant milestone in advancing targeted therapies for a challenging cancer type, offering new hope for patients in need of effective treatment options
- In 2020, Pfizer secured FDA accelerated approval for Trodelvy (sacituzumab govitecan-hziy) in treating metastatic triple-negative breast cancer. This approval underscored the drug's potential in addressing a previously limited therapeutic landscape, providing a promising option for patients facing the challenges of this aggressive form of breast cancer.
To know more about the study, visit https://www.databridgemarketresearch.com/fr/reports/global-antibody-drug-conjugates-market
The Prominent Key Players Operating in the Global Antibody Drug Conjugates (ADC) Market Include:
- Seagen Inc. (U.S.)
- Genentech Inc. (U.S.)
- Pfizer Inc. (U.S.)
- Novartis AG (Switzerland)
- F. Hoffmann-LA Roche Ltd. (Switzerland)
- Bristol -Myers Squibb (U.S.)
- Merck & Co., Inc. (U.S.)
- Immunomedics Inc.(U.S.)
- Takeda Pharmaceutical Company Limited (Japan)
- Onconova Therapeutics (U.S.)
- Helsinn Healthcare SA (Switzerland)
- Abbott (U.S.)
- Boehringer Ingelheim International GmbH (Germany)
- Johnson & Johnson Private Limited (U.S.)
- DAIICHI SANKYO COMPANY, LIMITED. (Japan)
- AbbVie Inc. (U.S.)
Above are the key players covered in the report, to know about more and exhaustive list of global antibody drug conjugates (ADC) market companies, contact: https://www.databridgemarketresearch.com/fr/contact
Research Methodology: Global Antibody Drug Conjugates (ADC) Market
Data collection and base year analysis are done using data collection modules with large sample sizes. The market data is analyzed and estimated using market statistical and coherent models. In addition, market share analysis and key trend analysis are the major success factors in the market report. The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, global vs Regional and Vendor Share Analysis. Please request analyst call in case of further inquiry.
